By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nektar Therapeutics (Alabama) 

1112 Church Street

Huntsville  Alabama  35801  U.S.A.
Phone: 256-512-9200 or 877-451-6587 Fax: 256-704-7647


Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in the U.S. andJapan for patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Key Statistics

Ownership: Public

Web Site: Nektar (Alabama)
Employees: 454
Symbol: NKTR


Company News
Nektar Therapeutics (AL) (NKTR) Release: Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at American Association for Cancer Research Annual Meeting 2013 4/8/2013 6:13:26 AM
Nektar Therapeutics (AL) (NKTR)'s NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 6/6/2011 11:20:58 AM
Nektar Therapeutics (AL) (NKTR) Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 American Society of Clinical Oncology Annual Meeting 5/19/2011 10:55:10 AM
FDA Grants Orphan Drug Designation For Nektar Therapeutics (AL) (NKTR)'s Investigational Drug (NKTR) 4/21/2011 7:34:20 AM
Nektar Therapeutics (AL) (NKTR) Prices Public Offering of Common Stock 1/19/2011 7:07:26 AM
Nektar Therapeutics (NKTR) Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010 11/15/2010 6:37:20 AM
Nektar Therapeutics (NKTR) Reports Third Quarter 2010 Financial Results 11/5/2010 7:08:49 AM
Nektar Therapeutics (NKTR) To Supply Polymer To Amgen (AMGN), Nektar Will Receive $50 Million 11/2/2010 6:25:29 AM
Nektar Therapeutics (NKTR) to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets 10/29/2010 9:46:52 AM
Nektar Therapeutics (NKTR) To Present at the UBS 2010 Global Life Sciences Conference 9/20/2010 8:30:30 AM